Assessment of health-related quality of life (HRQL) in PROSELICA: A Phase 3 trial assessing cabazitaxel 20 mg/m2 (C20) vs 25 mg/m2 (C25) in post-docetaxel (D) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
2018 ◽
Vol 19
(10)
◽
pp. 1404-1416
◽
2015 ◽
Vol 16
(5)
◽
pp. 509-521
◽
2015 ◽
Vol 15
(6)
◽
pp. 941-949
◽
2018 ◽
Vol 36
(15_suppl)
◽
pp. 5010-5010
◽